NextCure NXTC Stock
NextCure Price Chart
NextCure NXTC Financial and Trading Overview
| NextCure stock price | 1.5 USD |
| Previous Close | 1.62 USD |
| Open | 1.62 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 800 |
| Day's Range | 1.62 - 1.7 USD |
| 52 Week Range | 1.16 - 5.27 USD |
| Volume | 10.13K USD |
| Avg. Volume | 51.57K USD |
| Market Cap | 46.48M USD |
| Beta (5Y Monthly) | 0.055877 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.25 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.33 USD |
NXTC Valuation Measures
| Enterprise Value | -91999696 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.692946 |
| PEG Ratio (5 yr expected) | 0.02 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.3007925 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 1.349 |
Trading Information
NextCure Stock Price History
| Beta (5Y Monthly) | 0.055877 |
| 52-Week Change | -61.072% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.27 USD |
| 52 Week Low | 1.16 USD |
| 50-Day Moving Average | 1.64 USD |
| 200-Day Moving Average | 1.94 USD |
NXTC Share Statistics
| Avg. Volume (3 month) | 51.57K USD |
| Avg. Daily Volume (10-Days) | 31.46K USD |
| Shares Outstanding | 27.83M |
| Float | 18.53M |
| Short Ratio | 3.57 |
| % Held by Insiders | 8.75% |
| % Held by Institutions | 50.22% |
| Shares Short | 236.09K |
| Short % of Float | 0.85% |
| Short % of Shares Outstanding | 0.85% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.11% |
| Return on Equity (ttm) | -38.15% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -54199000 USD |
| EBITDA | -68183000 USD |
| Net Income Avi to Common (ttm) | -70227000 USD |
| Diluted EPS (ttm) | -2.57 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 145.49M USD |
| Total Cash Per Share (mrq) | 5.23 USD |
| Total Debt (mrq) | 7.01M USD |
| Total Debt/Equity (mrq) | 4.55 USD |
| Current Ratio (mrq) | 23.766 |
| Book Value Per Share (mrq) | 5.552 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -53218000 USD |
| Levered Free Cash Flow (ttm) | -30738624 USD |
Profile of NextCure
| Country | United States |
| State | MD |
| City | Beltsville |
| Address | 9000 Virginia Manor Road |
| ZIP | 20705 |
| Phone | 240 399 4900 |
| Website | https://www.nextcure.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 99 |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Q&A For NextCure Stock
What is a current NXTC stock price?
NextCure NXTC stock price today per share is 1.5 USD.
How to purchase NextCure stock?
You can buy NXTC shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NextCure?
The stock symbol or ticker of NextCure is NXTC.
Which industry does the NextCure company belong to?
The NextCure industry is Biotechnology.
How many shares does NextCure have in circulation?
The max supply of NextCure shares is 35.72M.
What is NextCure Price to Earnings Ratio (PE Ratio)?
NextCure PE Ratio is now.
What was NextCure earnings per share over the trailing 12 months (TTM)?
NextCure EPS is -2.25 USD over the trailing 12 months.
Which sector does the NextCure company belong to?
The NextCure sector is Healthcare.
NextCure NXTC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
- {{ link.label }} {{link}}